Itt az első amerikai gyógyszer, ami kannabiszból készült

Epidiolex néven került forgalomba az a vadkenderből készült gyógyszer, melyet az USA Élelmiszerbiztonsági és Gyógyszerészeti Hivatala (FDA) is jóvá hagyott. Az orvosi kannabiszt tartalmazó szer hatóanyaga a kannabidiol, ami egy nem pszichoaktív kannabinoid molekula, és a kendernövényben, illetve a virágzatában található meg.

 

View this post on Instagram

 

A post shared by ＬＡＧＵＮＡ ＣＢＤ (@lagunacbd) on Jun 25, 2018 at 5:35pm PDT

Közel 50 államban írhatják fel orvosok, és napi kétszer vehető be szájon át a készítmény előírt adagja, akár már kétéves kortól kezdődően. Az epilepszia tüneteit csillapítja kétféle betegség esetén: ha Dravet- vagy Lennox-Gastaut-szindróma áll fenn.

A már pici gyerekkortól rohamok formájában jelentkező ritka, genetikus eredetű agyi funkciózavarokat új módokon közelítette meg a GW Pharmaceuticals. A cég vezérigazgatója, Justin Gover elárulta, hogy sorozatos klinikai tesztelés előzte meg a gyógyszer forgalomba hozását.

 

View this post on Instagram

 

Does cannabis help seizures? “Evidence from laboratory studies, anecdotal reports, and small clinical studies from a number of years ago suggest that cannabidiol, a non-psychoactive compound of cannabis, could potentially be helpful in controlling seizures. Conducting studies can be difficult as researchers have limited access to marijuana due to federal regulations and even more limited access to cannabidiol; there are also increased financial and time constraints. Cannabidiol (CBD) Open-label studies in the U.S. of Epidiolex (a drug derived from cannabidiol or CBD) are being performed. Epidiolex is a purified, 99% oil-based CBD extract from the cannabis plant and is produced by GW Pharmaceuticals to give known and consistent amounts in each dose. The U.S. Food and Drug Administration (FDA) has given some epilepsy centers permission to use this drug as “compassionate use” for a limited number of people at each center. Results from 214 people who received Epidiolex (99% CBD) in an open-label study (without a placebo control) and who completed 12 weeks or more on the drug were published in Lancet Neurology. -People who received Epidiolex ranged from 2 to 26 years old with an average age of 11. -All had epilepsy that did not respond to currently available treatments. -During the study, seizures decreased by an average of 54%. -People taking the anti-seizure medication clobazam (Onfi) seemed to have a better response when compared to those that were not on this medication.” To learn more, contact us or come visit us at 514-505-4666, 57 Rue Saint-Anne de Bellevue. http://57sainteanne.com #cannanecdotes #cannawellness #montrealcannabis #mtlcannabis #mtlcannabis #quebeccannabis #canadacannabis #seizuresandcannabis #epilepsy #epilepsyandcannabis #reducingseizures #epidiolex

A post shared by Le 57 – Saint Anne De Bellevue (@le57_sainteanne) on May 17, 2018 at 11:17am PDT

A rohamok 25-28 százalékkal kevesebbszer törtek azokra a páciensekre, akiket az Epidiolex-szel kezeltek, mint a placebót kapott kontroll csoport tagjaira. Mellékhatásként a szedéssel viszont álmatlanság, csökkenő étvágy, hasmenés és májenzim-változások járhatnak, teszi hozzá a CNN.

 

View this post on Instagram

 

AKA they revealed just how much they’ll be price gouging families and their children living with serious epilepsy conditions.. – U.K. company #GWPharmaceuticals just disclosed how much their new CBD-based epilepsy drug #Epidiolex will cost. – Epidiolex was approved for use in the U.S. by the FDA in June – for Dravet Syndrome and Lennox-Gastaut syndrome, 2 rare & very serious forms of epilepsy that can cause hundreds of seizures a day. The drug is the first medication derived from cannabis to get #FDA approval. – ? In a conference call with investors on Tuesday, the company announced that Epidiolex will cost each patient about $32,500 per year. – They said the cost was comparable to that of other drugs used to treat severe forms of epilepsy… – GW Pharma CEO Justin Gover said Epidiolex will provide a reliable and safe #cannabinoid treatment for patients. – ??? “This first U.S. approval not only represents a transformative milestone for our company but a historic medical breakthrough, offering patients and their families the first and only FDA approved CBD medicine to treat two severe, childhood-onset epilepsies,” Gover said. “These deserving patients will soon have access to a cannabinoid medicine that has been thoroughly studied in clinical trials, manufactured to assure quality and consistency, and available by prescription under a physician’s care.” – GW Pharmaceuticals North American president said that the cost for patients with health insurance will likely be much less. ? “The cost of a co-pay [for Epidiolex] is significantly—or could be significantly—less onerous and burdensome than the cost of the product either over the internet or from [a] dispensary..” – ☝️ Before Epidiolex can be prescribed in the U.S., the DEA must reschedule #CBD under the #ControlledSubstancesAct, which this company expects will happen quite soon. — Check out the full article at HighTimes.com for more info on the drug, the cost, rescheduling barrier, and more.

A post shared by High Times (@hightimesmagazine) on Aug 10, 2018 at 11:10am PDT